technologynetworks

Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada

Trelstar® (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer, is now available in a six-month dosing option (22.5 mg). The new dosing ...
FierceBiotech

Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA

TRELSTAR (R), developed by Debiopharm Group, a Swiss biopharmaceutical development specialist, and marketed by Watson Pharma, Inc., is a synthetic hormone known as a luteinizing hormone releasing ...
FierceBiotech

Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer

LAUSANNE, Switzerland, Nov. 13 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly ...
Medindia

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer

MORRISTOWN, N.J., March 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S. Food and Drug Administration (FDA) approval of ...
Monthly Prescribing Reference

Trelstar 22.5mg approved for palliative treatment of prostate cancer

TRELSTAR (triptorelin pamoate) 22.5mg injectable suspension from Watson The FDA has approved Trelstar 22.5mg (triptorelin pamoate for injectable suspension, from Watson) for the palliative treatment ...
Renal & Urology News

FDA Clears a Six-Month Trelstar Formulation

Watson Pharmaceuticals has received FDA approval of Trelstar (triptorelin pamoate for injectable suspension) 22.5 mg, the first and only six-month intramuscular gonadotropin releasing hormone (GnRH) ...
Nasdaq

Knight Partners With Debiopharm for the Commercialization of Trelstar® in Canada

MONTREAL and LAUSANNE, Switzerland, Jan. 8, 2020 /PRNewswire/ -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a Swiss-based, ...
Monthly Prescribing Reference

FDA approves MixJect system for Trelstar

MixJect, a drug delivery system, has been approved for use with Watson’s Trelstar Depot and Trelstar LA (triptorelin pamoate injectable suspension). MixJect features a smaller 21-gauge needle, ...
The Korea Herald

DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA

LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational ...
Business Insider

Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America

Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding ...
Medindia

Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer

CORONA, Calif., Nov. 13 Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its New Drug Application (NDA) for a 6-month formulation of ...